476 related articles for article (PubMed ID: 21283094)
1. Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
[No Abstract] [Full Text] [Related]
2. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
3. 2013 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
[No Abstract] [Full Text] [Related]
4. Regulatory watch: crossing the regulatory finish line.
Tse MT
Nat Rev Drug Discov; 2012 Jun; 11(7):509. PubMed ID: 22743970
[No Abstract] [Full Text] [Related]
5. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
Khozin S; Liu K; Jarow JP; Pazdur R
Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
[No Abstract] [Full Text] [Related]
6. FDA not NIH can speed new drugs.
Miller HI
Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
[No Abstract] [Full Text] [Related]
7. Examining Manufacturing Readiness for Breakthrough Drug Development.
Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
[No Abstract] [Full Text] [Related]
8. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
9. New FDA breakthrough-drug category--implications for patients.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
[No Abstract] [Full Text] [Related]
10. Drug development for neglected diseases - the trouble with FDA review vouchers.
Kesselheim AS
N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
[No Abstract] [Full Text] [Related]
11. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
12. Adverse effects in women: implications for drug development and regulatory policies.
Parekh A; Fadiran EO; Uhl K; Throckmorton DC
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):453-66. PubMed ID: 22114855
[TBL] [Abstract][Full Text] [Related]
13. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
[No Abstract] [Full Text] [Related]
14. Health, Wealth, and the 21st Century Cures Act.
Lo AW; Philipson TJ; von Eschenbach AC
JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
[No Abstract] [Full Text] [Related]
15. FDA approves AIDS drug.
Am Pharm; 1992 Sep; NS32(9):13-4. PubMed ID: 1332462
[No Abstract] [Full Text] [Related]
16. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
17. Regulatory watch: FDA PDUFA goals missed.
Hay M
Nat Rev Drug Discov; 2009 Jan; 8(1):10. PubMed ID: 19116619
[No Abstract] [Full Text] [Related]
18. Food and drug administration expanded access to treatment: implications for oncology patients.
Freedman RS; Markman M
Cancer; 2007 Jun; 109(11):2157-60. PubMed ID: 17450587
[No Abstract] [Full Text] [Related]
19. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
Kulynych J
Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
[No Abstract] [Full Text] [Related]
20. Is the priority review voucher program stimulating new drug development for tropical diseases?
Kerr KW; Henry TC; Miller KL
PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006695. PubMed ID: 30092022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]